INTRODUCTION
============

ADAM12 is a member of a disintegrin and metalloprotease (ADAM) protein family whose members are cell-surface multidomain proteins involved in ectodomain shedding, adhesion, and signaling activities ([@B11]). ADAM archetypes are transmembrane proteins that contain propeptide, extracellular metalloprotease, disintegrin-like, cysteine-rich, and epidermal growth factor (EGF)--like transmembrane and cytoplasmic domains.

In humans, the expression of ADAM12 is mainly associated with adult skeletal, cardiac, and smooth muscle cells and is dramatically increased in several pathologies, including cancer ([@B28]). Within tissues, ADAM12 up-regulation has been described in both cancer and stromal cells, and increased urine protein levels were also reported in patients with breast or bladder tumors. Genome-wide analyses of human tumors identified ADAM12 as a new candidate cancer gene ([@B55]), and it is now considered as a prognosis marker for human bladder cancer ([@B50]; [@B13]) and breast cancer ([@B49]; [@B41]). In support of its involvement in cancer, ADAM12 was shown to regulate tumor progression in genetically modified mouse models. However, the mechanism involved remains unclear ([@B29]; [@B46]).

The human ADAM12 gene is expressed as two alternatively spliced transcripts that give rise to transmembrane ADAM12L and secreted ADAM12S forms, the latter lacking the transmembrane and cytoplasmic domains. Both ADAM12 variants can act as proteases and have been shown to cleave IGFBP3 and IGFBP5 ([@B35]; [@B53]), EGF receptor ligands ([@B3]; [@B22]), Notch ligand Delta-like 1 ([@B10]), and placental oxytocinase ([@B26]). Besides its metalloprotease activity, the membrane-anchored ADAM12L long form is involved in cell--cell and cell--matrix interaction via its binding to cell-surface molecules that include integrins ([@B12]; [@B27]), syndecans ([@B25]), and type II transforming growth factor-β (TGF-β) receptor ([@B4]). However ADAM12L is not constitutively addressed to the membrane, and its distribution at the cell surface is a dynamic process that requires PKCɛ activation ([@B57]), recruitment of RACK1 ([@B6]), and c-Src activity ([@B56]). All these events take place in response to external cell stimulation such as integrin engagement and depend on the intracellular domain of ADAM12L, since its truncation prevents translocation of the protein ([@B23]). The cytoplasmic tail of ADAM12 has been shown to physically interact with several signaling proteins, including the Src nonreceptor tyrosine kinases c-Src and YES ([@B58]), the adapter proteins Grb2 ([@B58]) and Fish ([@B1]), the regulatory subunit of phosphatidylinositol 3-kinase, p85α ([@B3]), the cytoplasmic PACSIN3 phosphoprotein ([@B40]), eve-1, an EEN-binding protein implicated in shedding activity ([@B59]), and two actin-related proteins, α-actinin-1 and -2 ([@B16]; [@B7]). This complex protein interaction network contributes to the regulation of ADAM12L translocation and function and might in turn play a pivotal role in the coordination of cell signaling and responses to the microenvironment.

In liver cancer, we previously demonstrated that up-regulation of ADAM12 expression was associated with the activation of hepatic stellate cells (HSCs; [@B32]) and the regulation of the TGF-β signaling pathway ([@B4]). In addition, our data showed that type I collagen---the major collagen in fibrosis tissue---promoted the localization of ADAM12 to the surface of HSCs through a β1 integrin--dependent mechanism ([@B6]). In this study, we explored the ADAM12L protein interaction network using an integrative data-mining approach. We identify the integrin-linked kinase (ILK)---a kinase associated with human malignancies---as a new potential partner for ADAM12L. Our results demonstrate that ADAM12L coimmunoprecipitates with ILK and that stimulation of HSCs by type I collagen induces the recruitment of both proteins to focal adhesion-like structures. We show that down-regulation of ADAM12L leads to a loss of cell adhesion, whereas overexpression induces the Akt-dependent survival pathway and increases the kinase activity of ILK immunoprecipitates. We propose that ADAM12 plays a major role in adhesion-cell survival processes through enhancement of the β1 integrin/ILK/Akt signaling pathway.

RESULTS
=======

An ADAM12 protein interaction network as part of the integrin signaling network
-------------------------------------------------------------------------------

The interaction of ADAM12L with numerous receptors and intracellular signal mediators (listed in [Table 1](#T1){ref-type="table"}) suggests that it could act as a docking/signaling protein. Using the STRING database to extract direct (physical) and indirect (functional) associations between proteins, we built the ADAM12L protein interaction network shown in [Figure 1](#F1){ref-type="fig"}. The high level of interconnections suggests strong associations with the same biological functions. The connectivity of the graph was next enriched by adding five known interactions not yet incorporated in the database, between ADAM12 and TGFBR2, GNB2L1, PRKCE, and PRKCD, and between Src and TGFBR2. Of interest, all known proteins identified as ADAM12-binding proteins were previously shown to be associated with Src. These include the four SH3 domain--containing proteins SH3D19, SH3PXD2A, YES1, and PACSIN3. In addition ADAM12 and Src both connect to the same subnetwork in which the integrin signaling pathway stands out. Because engagement of β1 integrin (ITGB1) by external stimuli has been recently associated with the Src-mediated modulation of ADAM12 subcellular distribution ([@B56]), we sought to investigate a possible interaction between ADAM12 and a major functional partner of integrins, ILK. Our rationale was that ILK directly binds to integrins in response to stimulation by the microenvironment, suggesting a pivotal role in signal transduction that might implicate ADAM12.

![The ADAM12L protein interaction network. The list of the 14 proteins that physically bind ADAM12L ([Table 1](#T1){ref-type="table"}) was used as input in the STRING application, and the graph was generated using default parameters. The interactions between ADAM12 and PRKCE ([@B57]), PRKCD ([@B3]), GNB2L1 ([@B6]), and TGFBR2 ([@B4]) and between TGFBR2 and Src ([@B17]) have not been entered in the database yet and were added manually (green connecting lines).](3461fig1){#F1}

###### 

ADAM12L-interacting proteins used as input for STRING application ([http://string-db.org](http://string-db.org/)).

  Gene name   Description                                                              Experiment type
  ----------- ------------------------------------------------------------------------ -------------------------------------
  ACTN2       Actinin α2                                                               In vivo; in vitro; yeast two-hybrid
  ACTN1       Actinin α1                                                               In vivo; in vitro
  GRB2        Growth factor receptor--bound protein 2                                  In vivo
  SRC         V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homologue (avian)      In vivo; in vitro
  YES1        V-yes-1 Yamaguchi sarcoma viral oncogene homologue 1                     In vitro
  PIK3R1      Phosphoinositide-3-kinase regulatory subunit 1 (α)                       In vivo; in vitro
  PRKCE       Protein kinase C ε                                                       In vitro
  PRKCD       Protein kinase C δ                                                       Yeast two-hybrid
  ITGB1       Integrin β1 (fibronectin receptor β polypeptide, antigen CD29)           In vitro
  SH3PXD2A    SH3 and PX domains 2A                                                    In vivo; in vitro
  PACSIN3     Protein kinase C and casein kinase substrate in neurons 3                In vivo; in vitro; yeast two-hybrid
  SH3D19      SH3 domain containing 19                                                 In vivo; in vitro; yeast two-hybrid
  TGFBR2      Transforming growth factor β receptor II (70/80 kDa)                     In vivo; in vitro; yeast two-hybrid
  GNB2L1      Guanine nucleotide binding protein (G protein) β polypeptide 2--like 1   In vivo; in vitro; yeast two-hybrid

ADAM12 interacts with the ILK integrin-linked kinase
----------------------------------------------------

To test this hypothesis, we first investigated whether ADAM12 interacts with ILK in Cos7 cells, which do not express endogenous ADAM12. Endogenous ILK was immunoprecipitated from extracts of cells transfected with ADAM12L. As shown in [Figure 2A](#F2){ref-type="fig"}, both pro and processed ADAM12---the 110- and 90-kDa forms, respectively---were expressed in Cos7 cells (left) and coimmunoprecipitated with ILK (middle). The reverse immunoprecipitation was performed using a mix of ADAM12 monoclonal antibodies and blotted for ILK ([Figure 2A](#F2){ref-type="fig"}, right). The coimmunoprecipitation of ILK and ADAM12 was confirmed using transfection of V5-tagged ILK in either Cos7 cells transfected with ADAM12 or in the LX2 HSC line, which expresses low endogenous ADAM12 levels (Supplemental Figure S1). To show whether the interaction between ADAM12 and ILK occurs under physiological conditions, we used primary cultures of HSCs isolated from human liver tissues. Cell culture mimics the HSC activation process, which consists in the transition from a quiescent to a fibrogenic state. This is accompanied by increased expression of ADAM12 and ILK, as previously described in chronic liver diseases ([@B32]; [@B64]). The expression of endogenous ADAM12L in activated HSCs is shown in [Figure 2B](#F2){ref-type="fig"} (left). When immunoprecipitation was performed using ILK antibodies, ADAM12/ILK complexes were clearly detected in cell extracts ([Figure 2B](#F2){ref-type="fig"}, middle). The reverse immunoprecipitation using ADAM12 antibodies confirmed the endogenous interaction of ADAM12 and ILK ([Figure 2B](#F2){ref-type="fig"}, right).

![ADAM12L interacts with ILK. Cell extracts from (A) Cos7 cells transfected with the long form of ADAM12, ADAM12L, or (B) HSCs were immunoprecipitated with anti-ADAM12 or anti-ILK (IP) and immunoblotted with anti-ILK or anti-ADAM12 antibodies (IB). (C) Cos7 cells were transfected either with ADAM12L or the ADAM12-Δcyto cytoplasmic tail deletion or the short ADAM12S secreted form. Cell extracts were immunoprecipitated with anti-ILK and immunoblotted with anti-ADAM12 (right). Left, immunoblots performed on crude extracts as controls. (D) Cos7 cells transfected with ADAM12L were immunoprecipitated with anti-ILK and immunoblotted (IB) with anti-PINCH, anti-parvin, or anti-ADAM12 antibodies. (E) ADAM12L, ADAM12S, and ADAM12-Δcyto were expressed as His-tagged fusion proteins, and binding assays were performed by incubating His-ADAM12 bound to nickel-agarose with 1 μg of purified ILK. Interacting proteins were immunoblotted with anti-ILK and anti-ADAM12 antibodies.](3461fig2){#F2}

To identify the domain of ADAM12 that is required for interaction with ILK, we transfected Cos7 cells with ADAM12L, with a truncated form lacking the cytoplasmic domain (ADAM12-Δcyt) or with the ADAM12S short form. As shown in [Figure 2C](#F2){ref-type="fig"}, immunoprecipitation of ILK led to the recovery of high amounts of ADAM12L. In contrast, neither ADAM12L-Δcyt (90 kDa) nor ADAM12S (90 and 68 kDa for the precursor and processed forms, respectively) were detected in immunoprecipitates, implicating the ADAM12 cytoplasmic domain in the interaction with ILK. Because disintegrin and cysteine-rich domains are present in ADAM12L-Δcyt and ADAM12S and have been reported to interact with integrins ([@B12]; [@B27]; [@B60]; [@B65]; [@B24]; [@B30]), the lack of recovery of ADAM12L-Δcyt and ADAM12S in ILK immunoprecipitates suggests that integrins do not mediate the interaction of ADAM12 and ILK. In addition, we investigated the presence of PINCH and parvin in ILK-ADAM12 immune complexes isolated from cell extracts, as ILK has been linked to PINCH and parvin proteins in forming the IPP complex ([@B34]). As expected, both proteins were detected in ILK immunoprecipitates ([Figure 2D](#F2){ref-type="fig"}), suggesting that the interaction of ADAM12 and ILK takes place within IPP complexes.

To rule out the possible implication of additional proteins, we next investigated ADAM12/ILK interactions using recombinant proteins in in vitro binding assays. ILK was expressed as a glutathione *S*-transferase (GST) fusion protein and purified on glutathione-agarose beads before removal of the GST tag (recILK). We then performed pull-down assays by incubating recILK with purified histidine (His)-tagged ADAM12 variants. As shown in [Figure 2E](#F2){ref-type="fig"}, recILK only bound full-length ADAM12L, demonstrating an association that is both direct and specific. These results provide strong evidence for a direct interaction of the cytoplasmic domain of ADAM12L with ILK in cells. To investigate the functional relevance of the interaction between ADAM12 and ILK, we next explored the localization of both proteins in HSCs.

ADAM12 and ILK are recruited to focal adhesions upon β1 integrin stimulation
----------------------------------------------------------------------------

We previously showed that ADAM12 is stored in the cytoplasm and translocated to the membrane of HSCs upon stimulation by type I collagen ([@B6]). To investigate the dynamics of the interaction between ADAM12 and ILK, we immunolocalized ADAM12 and ILK in HSCs stimulated or not by type I collagen. As shown in [Figure 3A](#F3){ref-type="fig"}, immunostained ILK and ADAM12 were strongly redistributed to the cell surface when HSCs were plated on type I collagen. Similarly, in stimulated HSCs, ADAM12 colocalized with β1 integrin ([Figure 3B](#F3){ref-type="fig"}) and vinculin ([Figure 3C](#F3){ref-type="fig"}), a cytoskeletal focal adhesion protein involved in linkage of integrin adhesion molecules to the actin cytoskeleton. In agreement with these observations, the colocalization of ILK with β1 integrin was increased upon stimulation by type I collagen ([Figure 3D](#F3){ref-type="fig"}). We further demonstrated the involvement of β1 integrin in the redistribution of ILK and ADAM12 to focal adhesions by using anti--β1 integrin blocking antibodies. As shown in [Figure 3E](#F3){ref-type="fig"}, preincubation of HSCs with blocking antibodies inhibited the translocation of ADAM12 to the focal adhesions. These results suggest that activation of the integrin pathway by type I collagen induces the recruitment of both ADAM12 and ILK to focal adhesions.

![ADAM12L and ILK are recruited to focal adhesion structures upon β1 integrin stimulation. HSCs were cultured on plastic dishes (--) or on dishes coated with type I collagen (+) overnight in medium containing 2% FBS. Cell were immunostained with antibodies against anti-ADAM12, anti-ILK, anti-vinculin, and anti-ITGB1 as indicated, followed by tetramethylrhodamine isothiocyanate-- or fluorescein isothiocyanate--labeled secondary IgG. Representative fields are shown. Colocalization results in yellow cellular staining. (A) Localization of ADAM12 and ILK. (B) Localization of β1 integrin (ITGB1) and ADAM12. (C) Localization of vinculin and ADAM12. (D) Localization of ILK and β1 integrin. (E) HSCs were preincubated with anti--β1 integrin blocking antibodies or control mouse IgG1 before seeding on type I collagen. Scale bars, 10 μm.](3461fig3){#F3}

ADAM12 modulates hepatic stellate cell adhesion
-----------------------------------------------

Because ILK and ADAM12 are recruited to focal adhesions in stimulated HSCs ([Figure 3](#F3){ref-type="fig"}) and ILK has been previously associated with the fibrogenic phenotype of HSCs through its implication in cell adhesion ([@B52]), we next asked whether expression for ADAM12 could affect cell adhesion. We performed ADAM12 small interfering RNA (siRNA) knockdown in human HSCs. After 48 h of treatment, the steady-state levels of ADAM12 mRNA and proteins were significantly reduced in HSCs, indicating robust RNA interference efficiency ([Figure 4, A and B](#F4){ref-type="fig"}). Note that both the long and the short variants of ADAM12 were equally silenced, whereas expression of type I collagen and TGF-β, the two fibrogenic markers of HSCs used as controls, was not modified. During the course of this analysis, we observed changes in cell spreading, and we sought to examine the effect of ADAM12 on the cytoskeleton of HSCs by performing microscopy analysis of actin stress fibers ([Figure 4C](#F4){ref-type="fig"}). Type I collagen induced prominent stress compared with control cultures on plastic dishes. In addition, we found that inhibition of ADAM12 expression led to a striking disorganization and retraction of stress fibers, suggesting major changes in cell spreading and adhesion processes. In line with this conclusion, ADAM12 silencing in HSCs led to a significant decrease in adherent cells cultured on plastic dishes (26 ± 2.5 and 40 ± 2.7% decrease at 24 and 48 h, respectively; [Figure 4D](#F4){ref-type="fig"}, left). Cultivating HSCs on type I collagen delayed this effect, probably by mobilizing more integrins. However, a significant reduction in adherent cells (35.6 ± 2.8%) was observed at 48 h under these growth conditions. In agreement with this observation, ADAM12-silenced cells plated onto type I collagen, fibronectin, or laminin, which engage different integrins, showed a reduced loss of cell adhesion compared with an albumin plating control ([Figure 4D](#F4){ref-type="fig"}, right).

![RNA interference--mediated decreased expression of ADAM12 in hepatic stellate cells induces actin cytoskeleton reorganization and loss of adhesion. HSCs were transfected with 2 nM nontargeted siRNA (Scr) or ADAM12L siRNA (siADAM12). After 48 h, Western blotting (A) and real-time PCR analyses (B) were used to confirm the efficiency and specificity of RNA interference in cell extracts. PCR controls included ADAM12S, type I collagen (Col1), and TGF-β. (C) Transfected cells were analyzed by phase-contrast microscopy (left) and stained with rhodamine-conjugated phalloidin to monitor actin stress fibers (right). Nuclei were counterstained using 4′,6-diamidino-2-phenylindole (blue). (D) Cell adhesion was evaluated by counting adherent cells vs. cells released in the medium at 24 and 48 h posttransfection. Results are expressed as the percentage of adherent cells and represented as the mean ± SD of three independent experiments (\**p* \< 0.05; \*\*, ^\#\#^*p* \< 0.01). Left, Cell adhesion on plastic and collagen type I compared 24 and 48 h posttransfection. Right, cell adhesion on different substrates compared 24 h posttransfection.](3461fig4){#F4}

The effect of ADAM12 silencing on cell adhesion was maximal at 48 h. Over longer times, expression of ADAM12 resumed in HSCs transiently transfected with siADAM12 (Supplemental Figure S2A). Note that all cells recovered in the culture supernatants after transfection with ADAM12 siRNAs no longer expressed ADAM12. In addition, cell death was unaffected in HSCs transfected with siADAM12 (Supplemental Figure S2B). This conclusion is further supported by the demonstration that overexpression of ADAM12 in CHO cells treated with staurosporine or tumor necrosis factor--related, apoptosis-inducing ligand did not significantly protect cells against death (Supplemental Figure S3). Because ILK plays an important role in the regulation of cell proliferation and migration ([@B39]), we also sought to explore how ADAM12 overexpression could modulate these effects. As shown in Supplemental Figure S4, ADAM12 induced only a slight but significant increase in cell proliferation (Supplemental Figure S4A) and migration (Supplemental Figure S4B).

On the basis of the physical and functional association of endogenous ADAM12 and ILK in HSCs, we next explored which signaling pathway(s) might be involved in this effect.

Expression of ADAM12 reinforces the Akt signaling pathway
---------------------------------------------------------

Cell adhesion to the extracellular matrix is mediated by the integrin-stimulated, ILK-dependent pathway, which involves protein kinase B (Akt) and GSK-3. To examine whether expression of ADAM12 modulates Akt and GSK-3 activation, we transfected Cos7 cells with wild-type and mutant ADAM12 constructs for 48 h and further plated them on type I collagen--coated dishes. Phosphorylation of Akt and GSK-3 was examined by Western blot analysis at the times indicated in [Figure 5](#F5){ref-type="fig"}. Overexpression of ADAM12L significantly enhanced Akt and GSK-3 phosphorylation compared with cells transfected with an empty vector ([Figure 5A](#F5){ref-type="fig"}). Of interest, this induction was independent of the proteolytic activity of ADAM12L, since the catalytically deficient ADAM12-E351Q mutant induced Akt and GSK-3 phosphorylation to an extent similar to that of wild-type ADAM12L ([Figure 5B](#F5){ref-type="fig"}). Neither the ADAM12-Δcyt truncated form nor the ADAM12S secreted form, neither of which binds ILK ([Figure 1D](#F1){ref-type="fig"}), could induce Akt and GSK-3 phosphorylation ([Figure 5C](#F5){ref-type="fig"}), establishing that the effect of ADAM12L on the Akt signaling pathway is specific.

![Expression of ADAM12L augments phosphorylation of Akt and GSK-3. Cos7 cells were transfected with empty vector (control) or ADAM12 constructs and cultured for 48 h. The cells were then plated on dishes coated with type I collagen for the indicated times, and the levels of phosphorylated Akt (Akt P-S^473^), phosphorylated GSK-3β (GSK3β P-S^9^), total Akt, and GSK-3β were determined by Western blot analysis (IB). Results are expressed as the mean ± SD of three independent experiments (\**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.01). (A) ADAM12L vs. control. (B) ADAM12L vs. the catalytically deficient ADAM12-E351Q mutant. (C) ADAM12L vs. ADAM12S and ADAM12-Δcyto (time, 60 min).](3461fig5){#F5}

To determine whether this stimulating effect was dependent on ILK and β1 integrin, we assessed the phosphorylation status of Akt in cells either silenced for ILK or preincubated with anti--β1 integrin blocking antibodies. Down-regulation of ILK expression ([Figure 6A](#F6){ref-type="fig"}) or inhibition of β1 integrin ([Figure 6B](#F6){ref-type="fig"}) both diminished Akt phosphorylation induced by overexpression of ADAM12L, implicating β1 integrin and ILK in mediating the effect of ADAM12L. In line with this conclusion, adhesion on type I collagen of HSCs, which express high basal levels of ADAM12L, induced a similar phosphorylation of Akt and GSK3 ([Figure 6C](#F6){ref-type="fig"}).

![Induction of Akt phosphorylation by ADAM12L expression requires ILK and stimulation of integrin β1 and PI3K activity. (A) Cos7 cells were cotransfected with 2 nM nontargeted siRNA (Scr) or ILK siRNA (siILK) and empty vector (control) or the ADAM12 construct. Cells were cultured for 48 h, serum starved, and then plated onto dishes coated with type I collagen for 1 h. Levels of phosphorylated Akt (Akt-P-S^473^) were determined by Western blot analysis (IB); immunoblots for ILK, ADAM12, and actin are shown as controls. (B) Cos7 cells were transfected with ADAM12 constructs, cultured for 48 h, and incubated with anti--β1 integrin blocking antibodies for 30 min before plating on plastic dishes or dishes coated with type I collagen for 1 h. Levels of phosphorylated Akt (Akt-P-S^473^) were determined by Western blot analysis (IB); immunoblots for ILK, ADAM12, and actin are shown as controls. (C) Adhesion of HSCs on type I collagen augments phosphorylation of Akt and GSK-3. HSC cells were plated onto dishes coated with type I collagen for the indicated times, and the levels of phosphorylated Akt (Akt P-S^473^), phosphorylated GSK-3β (GSK3β P-S^9^), total Akt, and GSK-3β were determined by Western blot analysis (IB). Immunoblots for endogenous ADAM12 and actin are shown as controls. (D) Cos7 cells were transfected with empty vector (control) or ADAM12L constructs and cultured for 48 h. The cells were then incubated with the PI3K inhibitor wortmannin (100 nM) or LY294002 (10 μM) and further plated onto type I collagen--coated dishes for 1 h. Levels of phosphorylated Akt (Akt-P-S^473^) were determined by Western blot analysis (IB); immunoblots for ILK, ADAM12, and actin are shown as controls.](3461fig6){#F6}

To further explore the molecular mechanisms underlying this novel modulation of the Akt pathway by ADAM12L, we next analyzed the involvement of phosphoinositide 3-kinase (PI3K), an upstream-acting kinase that regulates ILK activity ([@B9]). For this purpose, we evaluated the effects of two PI3K inhibitors, wortmannin and LY294002, on Akt phosphorylation. Transfected cells were preincubated with the inhibitors before plating on type I collagen for 60 min, and Akt phosphorylation was analyzed by Western blotting. As shown in [Figure 6D](#F6){ref-type="fig"}, wortmannin and LY294002 both blocked the ADAM12L-dependent induction of Akt phosphorylation, implicating PI3K activity in this phenomenon.

Providing additional support for the role of ADAM12L in the promotion of the ILK/Akt-dependent pathway, ILK immunoprecipitates from extracts of cells overexpressing ADAM12L directly phosphorylated the downstream GSK-3 Crosstide peptide substrate (CT-GSK-3), whereas phosphorylation of CT-GSK-3 was very low in the absence of ADAM12 ([Figure 7](#F7){ref-type="fig"}). This effect was correlated with the concentration of ADAM12L in cells ([Figure 7A](#F7){ref-type="fig"}) and was specific to ADAM12L and dependent on ILK, since the phosphorylation of CT-GSK-3 in cells overexpressing ADAM12S was similar to that in control and in ILK-silenced cells ([Figure 7B](#F7){ref-type="fig"}). Taken together, the results of these experiments demonstrate that ADAM12L expression augments the Akt/GSK3 signaling pathway in response to microenvironment stimulation via a β1 integrin/PI3K/ILK--dependent pathway.

![ADAM12L expression induces GSK3 phosphorylation in ILK immunoprecipitates. Cos7 cells were transfected with (A) increasing amounts of ADAM12L or (B) empty vector (control), ADAM12L, ADAM12S, nontargeted siRNA (Scr), or ILK siRNA (siILK) in the presence of ADAM12L, as indicated. In vitro kinase assays were carried out by incubating ILK immunoprecipitated from the corresponding cell extracts with the GSK-3 Crosstide peptide substrate (CT-GSK-3). Representative autoradiographs show the amount of ^32^P incorporation, and results are expressed as the mean ± SD of three independent experiments.](3461fig7){#F7}

DISCUSSION
==========

Members of the ADAM protein family have emerged as important regulators of cell signaling through shedding activities of membrane-anchored cytokines or growth factors. Besides ligand processing, ADAMs have been proposed to function as signal transmitters. In the present study, we used an in silico approach based on protein integrative annotation to explore the intra­cellular protein interaction network of the transmembrane variant of ADAM12, ADAM12L. The resulting highly connected graph suggests that integrin signaling plays a critical role in the ADAM12L network. In agreement with this observation, the dynamic association of ADAM12 with Src upon integrin engagement was recently suggested to exert cooperative signals for cell proliferation, migration, and invasion ([@B56]). In addition, a functional association of ADAM12 with integrin signaling was implicated in the mesenchymal differentiation of adipocytes ([@B27]) and myogenic cells ([@B30]), in cell adhesion and spreading ([@B60]; [@B65]), migration ([@B24]), and invadopodia formation ([@B2]). However, the molecular mechanism linking ADAM12 to integrin signaling has remained unclear. We now provide evidence for the interaction of ADAM12 with the integrin-linked kinase ILK and demonstrate the role of ADAM12 in enhancing the functionality of the ILK/Akt signaling pathway upon integrin stimulation. ILK is found in most cells within the IPP complex formed together with PINCH and parvin ([@B34]). Our coimmunoprecipitation experiments show that the ILK/ADAM12 interaction we report can occur within these complexes and without disrupting them, highlighting the acquisition of a new functionality for IPP as a function of ADAM12 recruitment.

Dynamic translocation of ADAM12 with ILK to focal adhesions
-----------------------------------------------------------

In response to binding of integrins to matrix components, ILK associates with adaptor proteins and is recruited to nascent focal complexes enriched in docking and signaling proteins, including vinculin ([@B33]). In agreement with this dynamic translocation of ILK, we previously reported that stimulation of integrin pathways by type I collagen induces the recruitment of ADAM12 to the membrane of hepatic stellate cells ([@B6]). We now demonstrate that, similar to ILK, ADAM12 is redistributed within vinculin-rich structures at the cell surface of HSCs stimulated by type I collagen. This suggests that ADAM12 contributes to the dynamics of protein-complex formation at focal adhesions in HSCs. Transiently increased levels of ADAM12/β1 integrin--containing complexes have been reported at the cell surface of preadipocytes ([@B27]). Of interest, this study showed that forced expression of the ADAM12-Δcyto truncated protein, which spontaneously translocates to the membrane, also led to alterations of the actin cytoskeleton, cell adhesion, and survival. These observations suggest that the cytoplasmic tail of ADAM12 is required to sustain these functions. In support of this hypothesis, our data show that ADAM12 silencing induces loss of HSC adhesion and that the cytoplasmic tail of ADAM12 is required for the ILK-dependent survival pathway that correlates with cell adhesion.

Functional association of ADAM12 and ILK for Akt-dependent survival signaling
-----------------------------------------------------------------------------

Over the past several years, the in vivo and in vitro kinase activity of ILK has been widely debated, and ILK has been suggested to function as an adaptor/scaffold protein ([@B31]; [@B38]; [@B62]; [@B15]; [@B20]). Nevertheless, the classic ILK-dependent pathway involves a PI3K-dependent integrin engagement that leads to the phosphorylation of downstream Akt and GSK-3 targets. In addition, ILK properties can be modulated in vivo by complex protein interactions that result in activities triggered by the contextual environment, such as that found in cancer cells ([@B61]). In line with this notion, our data demonstrate that ADAM12, a protein specifically expressed in activated HSCs during chronic liver disease, enhances the activity of the ILK/Akt pathway in response to β1 integrin activation by type I collagen, the main matrix component of liver fibrosis. These results are in agreement with the reported implication of ILK pathway activity in the Akt-dependent regulation of fibroblast survival upon integrin stimulation ([@B42]).

The contextual association between ADAM12 and the ILK/Akt pathway is further supported by the correlation between ADAM12 and ILK expression. ADAM12 expression is associated with the undifferentiated proliferating state of mesenchymal cells such as chondrocytes in osteoarthritis ([@B45]), preadipocytes during high-fat diet--induced obesity ([@B37]), hepatic stellate cells in liver fibrosis ([@B32]), myoblasts during myogenic differentiation ([@B8]), and proliferating astroglial cells in injured brain ([@B5]). It is also involved in the initial steps of prekeratinocyte differentiation, where the absence of ADAM12 promotes migration, a differentiated feature of keratinocytes ([@B21]; [@B44]). Similar to ADAM12, increased activation of the ILK/Akt pathway has been associated with cell proliferation ([@B48]). In contrast, ILK knockdown in chondrocytes ([@B18]), keratinocytes ([@B36]), fibroblasts ([@B51]), and cortical cells ([@B43]) is not associated with a decrease in Akt phosphorylation, suggesting that, in differentiated cells, ILK could signal through an Akt-independent pathway. Taken together, these observations suggest that the specific expression of ADAM12 in proliferating undifferentiated mesenchymal-type cells might favor ILK/Akt pathway activity, thereby promoting the survival signaling pathway that is classically associated with cell adhesion.

Cooperative effects of ILK and ADAM12 in cancer
-----------------------------------------------

The ubiquitously expressed ILK is involved in tissue homeostasis. Elevated expression of ILK has been observed in tumors with poor prognosis and has been proposed as a new therapeutic target ([@B19]). Similarly, ADAM12 expression is markedly increased in numerous human cancers ([@B28]), and we previously reported the association of ADAM12 expression with liver fibrosis and cancer ([@B32]). In agreement with our results, ILK overexpression has also been shown to be associated with the activation of HSCs in liver fibrosis ([@B52]; [@B64]), and induction of ILK activity has been correlated with an increased activation of Akt in hepatocellular carcinomas ([@B47]). In line with these observations, the expression of ADAM12 in mammary-gland tumor cells was recently associated with increased cell proliferation and Akt phosphorylation levels ([@B14]). Similar to results reported in the present study, this effect was independent of the proteolytic activity of ADAM12, suggesting that the protumorigenic effect of ADAM12 is mediated by the disintegrin- and cysteine-rich domains that interact with integrins ([@B12]; [@B27]; [@B60]; [@B65]; [@B24]; [@B30]). Of interest, we previously showed that these same domains also interact with the TβRII receptor of TGF-β ([@B4]), which affects cell survival and proliferation through a PI3K/Akt--dependent pathway ([@B54]; [@B63]). These data reinforce the notion that ADAM12 might act as a scaffolding protein for integrin- and TGF-β receptor--dependent pathways, leading to the activation of PI3K/ILK/Akt signals and thereby affecting cancer cell survival.

In conclusion, results of this study, which identify ILK as a new ADAM12 partner, unravel a major aspect of the biological significance of the functional association of ADAM12 with the integrin signaling pathway. In addition, induction of the ILK/Akt pathway by ADAM12 suggests a potential role for this protein in cell adhesion and survival. According to this view, ADAM12 would act as a pivotal sensor implicated in the regulation of a microenvironment-dependent equilibrium between differentiation and proliferation.

MATERIALS AND METHODS
=====================

Cell culture and transfection
-----------------------------

HSCs were isolated from histologically normal specimens of partial hepatectomies from patients undergoing hepatic resection for liver metastases, as previously described ([@B32]). HSC and Cos7 cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS). For all experiments, cultured HSCs were used between passages 4 and 10. When specified, cells were plated on collagen type I--coated dishes (BD Biosciences, San Diego, CA) or Permanox chamber slides (Lab-Tek, Nalge Nunc International, Rochester, NY). HSCs were transfected using the Amaxa protocols and kits (Amaxa Biosystems, Cologne, Germany) according to the manufacturer\'s instructions. In some experiments, cells were incubated with PI3K inhibitors, 100 nM wortmannin (Calbiochem, Darmstadt, Germany), or 10 μM LY294002 (Calbiochem) for 30 min or anti-ITBG1 blocking antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) for 30 min at 37°C under agitation without FBS. To knock down ADAM12 and ILK expression, we used synthetic double-stranded ADAM12 siRNAs from Sigma-Aldrich (Saint-Quentin, France). The expression vectors for ADAM12 and mutants thereof, including the complete deletion of the cytoplasmic tail (ADAM12-Δcyt) and the protease-inactive mutant ADAM12-E351Q, were a gift from U. Wewer (Biotech Research and Innovation Center, University of Copenhagen, Copenhagen, Denmark). The expression vector for ILK was a gift from S. Dedhar (Department of Integrative Oncology, BC Cancer Research Center, Vancouver, Canada).

Adhesion assays
---------------

Cell adhesion was measured using a trypsinization assay. Briefly, HSCs transfected with 2 nM nontargeted siRNA (Scr) or ADAM12L siRNA (siADAM12) were plated onto collagen type I--, laminin-, and fibronectin-coated dishes or multiwell plates (BD Biosciences) for the indicated times in the absence of serum. Cells were then treated with 0.5 ml of 0.05% trypsin-EDTA for 4 min. Detached cells were collected in medium containing 10% serum and manually counted. Numbers of detached cells expressed as percentage of total were determined from three independent experiments. Controls included uncoated dishes and albumin-coated dishes (10 mg/ml in phosphate-buffered saline \[PBS\]).

Cell proliferation and migration assays
---------------------------------------

Cos7 cells were transfected with ADAM12 or control vectors and cultured for 48 h. Cells were then trypsinized, equilibrated in medium for 1 h at room temperature, and plated on collagen type I--coated dishes. For cell proliferation assay, the medium was replaced with DMEM containing 2% FCS in the presence of \[^3^H\]thymidine and incubated for the indicated times. Cells were scraped in PBS, sonicated for 10 min, and treated overnight with 30% trichloroacetic acid (TCA). Cell extracts were centrifuged, and the pellets homogenized in formic acid were used for counting TCA-precipitable radioactivity. For migration assays, cells seeded on type I collagen were incubated for 1 h at 37°C before addition of 2.5 μg/ml mitomycin C. After 24 h, the confluent monolayer was scratched using a pipette tip, and images were captured at the indicated times.

Western blotting and immunoprecipitation
----------------------------------------

Cell lysates were subjected to SDS--PAGE and transferred to nitrocellulose membranes (GE Healthcare, Little Chalfont, United Kingdom). Blots were incubated for 30 min in Tris-buffered saline containing 0.1% Tween 20 and 5% nonfat dry milk and further incubated for 2 h (or overnight at 4°C) with the following antibodies: rabbit anti-ADAM12 (a gift from U. Wewer), rabbit anti-ILK (Cell Signaling Technology, Boston, MA), and monoclonal anti--β-actin-peroxidase (Sigma-Aldrich). Antibodies against phospho-Akt (Ser-473), Phospho-GSK-3β (Ser-9), total Akt, total GSK-3 and α-parvin (D7F9) were from Cell Signaling Technology. PINCH antibodies were from BD Transduction Laboratories (Heidelberg, Germany). Bound antibodies were visualized with horseradish peroxidase--conjugated antibodies using an enhanced chemiluminescence system (Millipore, Billerica, MA). For immunoprecipitation, cell extracts were incubated with cross-linked ILK beads for 2 h at 4°C or preincubated for 1 h with protein G--Sepharose beads (GE Healthcare, Freiberg, Germany) alone to reduce nonspecific protein binding, followed by adsorption overnight to protein G--Sepharose beads prebound with 2 μg of specific or control ADAM12 rabbit immunoglobulin G (IgG). The beads were washed five times, and samples were analyzed by SDS--PAGE and immunoblotting.

Expression of recombinant proteins
----------------------------------

pET102D-His-ADAM12 and pGEX-GST-ILK constructs were transformed in BL21-DE3 (Novagen, EMD4Biosciences, Gibbstown, NJ), and expression was induced by 0.25 mM isopropyl 1-thio-α-[d]{.smallcaps}-galactopyranoside overnight at 18°C. Cells were harvested by centrifugation at 6000 × *g* for 15 min and lysed either in ice-cold PBS, pH 7.4 (137 mM NaCl, 2.7 mM KCl, 8 mM Na~2~HPO~4~, 1.5 mM KH~2~PO~4~) for GST-ILK or IMAC5 (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 5 mM imidazole) for His-ADAM12, and 0.1 mM 4-(2-aminoethyl-benzensulfonyl fluoride hydrochloride (AEBSF), complete EDTA-free protease inhibitor cocktail (Roche, Indianapolis, IN), and 1 mg/ml lysozyme. After 1 h of incubation on ice and two freeze/thaw cycles, the lysate was sonicated and clarified by centrifugation at 23,000 × *g* for 1 h at 4°C. His-ADAM12 was bound to Ni-charged Mag Beads (GenScript, Piscataway, NJ) for 1 h at 4°C. After washing with 10 bed volumes of IMAC20 (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 20 mM imidazole), the protein was eluted with IMAC 250 (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 250 mM imidazole) and dialyzed against PBS. GST-ILK was bound to GST MagBeads (GenScript) for 1 h at 4°C. After washing with 10 bed volumes of WB 300 (50 mM Tris-HCl, pH 8.0, 300 mM NaCl, 0.02% Tween 20, 0.1 mM AEBSF), the protein was eluted with 25 mM glutathione (Sigma-Aldrich) in PBS. The GST tag was cleaved with thrombin (1 U/10 μg in 25 mM Tris-HCl, pH 7.5, 1 mM dithiothreitol, 50 mM NaCl, 2.5 mM CaCl~2~) for 2 h at 30°C and immediately removed by chromatography on a GST MagBeads column. All protein fractions were concentrated on Ultracel YM 30 columns (Amicon, Millipore) and stored at −80°C.

Pull-down assays
----------------

His-ADAM12 in IMAC5 was bound to Ni-charged Mag-Beads (Qiagen, Hilden, Germany), for 90 min at 4°C, followed by three washes with IMAC5 buffer containing 5 mM imidazole, and incubated with ILK (wt/wt) for a 90 min incubation at 4°C. The nickel-agarose beads were further washed five times with 10 bed volumes of IMAC5 before elution with SDS--PAGE sample buffer. Samples were used for immunoblotting.

Immunostaining and imaging
--------------------------

To detect ADAM12, ILK, and ITGB1 in HSCs, we plated cells on Permanox Lab-Tek chamber slides for 48 h with 2% FBS and fixed them with 4% paraformaldehyde for 15 min. Cells were permeabilized with 0.1% Triton X-100 before incubation with rabbit anti-ADAM12 (rb122), mouse anti-ILK (Santa Cruz Biotechnology), rabbit anti-ILK1 (4G9; Cell Signaling Technology), mouse β1 integrin (Santa Cruz Biotechnology), or mouse anti-vinculin (Sigma-Aldrich) antibodies, followed by Alexa Fluor 488--conjugated anti-mouse and Alexa Fluor 555--conjugated anti-goat antibodies (Invitrogen, Karlsruhe, Germany), respectively. The slides were washed, mounted, and viewed using an automated DMRXA2 microscope (Leica, Wetzlar, Germany).

Relative quantifications of mRNA
--------------------------------

Reverse transcription-quantitative PCR was performed using the fluorescent dye SYBR Green methodology with the SybrTM Green I qPCRTM Core Kit (Eurogentec, Seraing, Belgium) and the ABI Prism 7300 thermocycler (PerkinElmer-Cetus, Foster City, CA) as previously described ([@B32]). The following primer pairs were used for the indicated target genes: ADAM12L, sense, 5′-CACCATTG­AAAAACTAAGGTGTGTG-3′, and antisense, 5′-GAGCCTGACAGGG­TTGGAAG-3′; ADAM12S, sense, 5′-CTGGGCACCTCCCTTCTGT-3′ and antisense, 5′-TGCTTCTGCTTGCCGGA-3′; type I collagen, sense, 5′-GGTCCTGATGGAAACAATGG-3′, and antisense, 5′-TTCCACCTTGAACACCCTGT-3′; TGF-β, sense, 5′-TGCGCTTGAGATCTTCAAACA-3′, and antisense, 5′-GGGCTAGTCGCACAGACCTC-3′; and 18S rRNA, sense, 5′-CGCCGCTAGAGGTGAAATTC-3′, and antisense, 5′-TTGGCAAATGCTTTCGCTC-3′.

In vitro kinase assays
----------------------

ILK immunoprecipitates were prepared using ILK antibodies cross-linked to magnetic protein G Dynabeads (Invitrogen). Cell extracts were incubated with cross-linked ILK beads for 2 h at 4°C and successively washed with extraction buffer and kinase assay buffer. Kinase assays were performed by incubating ILK immunoprecipitates with 1 μg/ml GSK-3 Crosstide peptide (Cell Signaling Technology) for 30 min at 30°C in reaction buffer (1 mM dithiothreitol, 10 μM ATP, 1 μCi of ^32^P-ATP, 0.01% Triton X-100, 25 mM Tris-HCl, pH 7.4, 50 mM NaCl, 10 mM MgCl~2~). The reaction was stopped by addition of SDS--PAGE sample buffer, and samples were used for immunoblotting and autoradiography analysis.
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ADAM

:   a disintegrin and metalloprotease

HSC

:   hepatic stellate cell

ILK

:   integrin-linked kinase

TGF-β

:   transforming growth factor-β
